Strategic risk management using complementary assets: Organizational capabilities and the commercialization of human genetic testing in the UK
No abstract is available for this item.
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Nightingale, Paul, 2004. "Technological capabilities, invisible infrastructure and the un-social construction of predictability: the overlooked fixed costs of useful research," Research Policy, Elsevier, vol. 33(9), pages 1259-1284, November.
- Nightingale, Paul & Poll, Robert, 2000. "Innovation in Investment Banking: The Dynamics of Control Systems within the Chandlerian Firm," Industrial and Corporate Change, Oxford University Press, vol. 9(1), pages 113-41, March.
- Susan Rose-Ackerman, 1996. "Altruism, Nonprofits, and Economic Theory," Journal of Economic Literature, American Economic Association, vol. 34(2), pages 701-728, June.
- Jonathan B. Wiener & Michael D. Rogers, 2002. "Comparing precaution in the United States and Europe," Journal of Risk Research, Taylor & Francis Journals, vol. 5(4), pages 317-349, October.
- Teece, David J., 1993.
"Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy,"
Elsevier, vol. 22(2), pages 112-113, April.
- Teece, David J., 1986. "Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy," Research Policy, Elsevier, vol. 15(6), pages 285-305, December.
- Simon, Herbert A, 1993.
"Altruism and Economics,"
American Economic Review,
American Economic Association, vol. 83(2), pages 156-61, May.
- Tripsas, Mary, 1997. "Surviving Radical Technological Change through Dynamic Capability: Evidence from the Typesetter Industry," Industrial and Corporate Change, Oxford University Press, vol. 6(2), pages 341-77, March.
- Kenneth J. Arrow, 1950. "A Difficulty in the Concept of Social Welfare," Journal of Political Economy, University of Chicago Press, vol. 58, pages 328.
- Zucker, Lynne G. & Darby, Michael R., 1997. "Present at the biotechnological revolution: transformation of technological identity for a large incumbent pharmaceutical firm," Research Policy, Elsevier, vol. 26(4-5), pages 429-446, December.
- Teece, David J., 1996. "Firm organization, industrial structure, and technological innovation," Journal of Economic Behavior & Organization, Elsevier, vol. 31(2), pages 193-224, November.
- Andrew Stirling, 1998. "Risk at a turning point?," Journal of Risk Research, Taylor & Francis Journals, vol. 1(2), pages 97-109, April.
- Greis, Noel P. & Dibner, Mark D. & Bean, Alden S., 1995. "External partnering as a response to innovation barriers and global competition in biotechnology," Research Policy, Elsevier, vol. 24(4), pages 609-630, July.
- Rosenberg, Nathan, 1990. "Why do firms do basic research (with their own money)?," Research Policy, Elsevier, vol. 19(2), pages 165-174, April.
- Rothwell, R. & Freeman, C. & Horlsey, A. & Jervis, V. T. P. & Robertson, A. B. & Townsend, J., 1974. "SAPPHO updated - project SAPPHO phase II," Research Policy, Elsevier, vol. 3(3), pages 258-291, November.
- Rothaermel, Frank T., 2001. "Complementary assets, strategic alliances, and the incumbent's advantage: an empirical study of industry and firm effects in the biopharmaceutical industry," Research Policy, Elsevier, vol. 30(8), pages 1235-1251, October.
When requesting a correction, please mention this item's handle: RePEc:eee:respol:v:35:y:2006:i:3:p:355-374. See general information about how to correct material in RePEc.
If references are entirely missing, you can add them using this form.